Hyperfine, Inc.
Close on Oct 19, 2026
- Market cap
- $77.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 14, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $3.90M | $-0.09 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $3.90M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $5.30M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 15, 2025 | After market close | $3.40M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | $2.70M | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $2.10M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | $2.32M | $-0.14 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $3.64M | $-0.14 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash burn | full year 2026 | $26.00M to $28.00M | New |
| revenue | full year 2026 | $20.00M to $22.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Hyperfine filed with the SEC
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Imaging System is Driving the Future of Brain Health Corporate Investor Deck – October 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperfine, Inc. Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Imaging System is Driving the Future of Brain Health Corporate Investor Deck – January 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperfine, Inc. Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine Announces Pricing of $17.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Hyperfine Reports Preliminary, Unaudited Results for Third Quarter 2025, Signaling Strong Business Momentum Following the Launch of the Next
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Imaging System is Driving the Future of Brain Health Corporate Investor Deck – October 2025 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, Inc.
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine Announces $6.0 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Portable MR Imaging system is driving the future of brain health. Corporate Investor Deck Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2025. All rights reserved. PROPERTY OF
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine, Inc. Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K/A
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
Other events · EX-99 to Form 8-K
Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperfine Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine Names Maria Sainz President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperfine Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Hyperfine Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 © 2022 Hyperfine, Inc.
Results of operations · EX-99.2 to Form 8-K
Hyperfine Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 © 2022 Hyperfine, Inc.
Results of operations · EX-99.2 to Form 8-K
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 2022 © 2022 Hyperfine, Inc.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperfine Reports Preliminary Unaudited 2021
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Defining the Future of Life-Saving
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “ Form 8-K ”)
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hyperfine Closes Business Combination with HealthCor
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K